Etiopathogenesis and epidemiology: Clues to etiology

Handbook of Multiple Sclerosis, Fourth Edition

Volumn , Issue , 2006, Pages 1-40

  Pryse Phillips, William ^a   Sloka, Scott ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42049093182     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (220)

1. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001; 22(2):117-139.
2. Jersild C, Fog T, Hansen GS, et al. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973; 2(7840):1221-1225.
3. Ebers GC, Sadovnick AD, Risen NJ. Canadian Collaborative Study Group. A genetic basis for familial aggregation in multiple sclerosis. Nature 1995; 377(6545):150-151.
4. Sadovnick AD, Armstrong H, Rice G, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993; 33(3):281-285.
5. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343(13):938-952.
6. Chataway J, Mander A, Robertson N, et al. Multiple sclerosis in sibling pairs: an analysis of 250 families. J Neurol Neurosurg Psychiatry 2001; 71(6):757-761.
7. Ebers GC, Yee IM, Sadovnick AD, Duquette P. Canadian Collaborative Study Group. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Ann Neurol 2000; 48(6):927-931.
8. Prokopenko I, Montomoli C, Ferrai R, et al. Risk for relatives of patients with multiple sclerosis in central Sardinia, Italy. Neuroepidemiology 2003; 22(5):290-296.
9. Montomoli C, Prokopenko I, Caria A, et al. Multiple sclerosis recurrence risk for siblings in an isolated population of Central Sardinia, Italy. Genet Epidemiol 2002; 22(3):265-271.
10. Compston A. The genetic epidemiology of multiple sclerosis. Philos Trans R Soc Lond B Biol Sci 1999; 354(1390):1623-1634.
11. Hupperts R, Broadley S, Mander A, Clayton D, Compston DA, Robertson NP. Patterns of disease in concordant parent-child pairs with multiple sclerosis. Neurology 2001; 57(2):290-295.
12. Sloka JS, Pryse-Phillips WE, Stefanelli M. Multiple sclerosis in Newfoundland and Labrador-a model for disease prevalence. Can J Neurol Sci 2005; 32(1):43-49.
13. Pugliatti M, Solinas G, Sotgiu S, Castiglia P, Rosati G. Multiple sclerosis distribution in northern Sardinia: spatial cluster analysis of prevalence. Neurology 2002; 58(2):277-282.
14. Kioy PG. Emerging picture of multiple sclerosis in Kenya. East Afr Med J 2001; 78(2):93-96.
15. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2(2):117-127.
16. Haase CG. Devics neuromyelitis optica. Disease or variants of multiple sclerosis? Nervenarzt 2001; 72(10):750-754.
17. Mirsattari SM, Johnston JB, McKenna R, et al. Aboriginals with multiple sclerosis:HLA types and predominance of neuromyelitis optica. Neurology 2001; 56(3):317-323.
18. Hawkes CH. Is multiple sclerosis a sexually transmitted infection? J Neurol Neurosurg Psychiatry 2002; 73(4):439-443.
19. Jin Y, de Pedro-Cuesta J, Soderstrom M, Stawiarz L, Link H. Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci 2000; 181(1-2):56-64.
20. Torrey EF, Miller J, Rawlings R, Yolken RH. Seasonal birth patterns of neurological disorders. Neuroepidemiology 2000; 19(4):177-185.
21. Salemi G, Ragonese P, Aridon P, et al. Is season of birth associated with multiple sclerosis? Acta Neurol Scand 2000; 101(6):381-383.
22. Willer CJ, Dyment D, Sadovnick AD, et al. Timing of birth and risk of multiple sclerosis:population based study. BMJ 2005; 330(7483):120.
23. Sumelahti ML, Tienari PJ, Wikstrom J, Salminen TM, Hakama M. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult Scler 2002; 8(4):350-355.
24. Warren S, Warren KG, Svenson LW, Schopflocher DP, Jones A. Geographic and temporal distribution of mortality rates for multiple sclerosis in Canada, 1965-1994. Neuroepidemiology 2003; 22(1):75-81.
25. Bronnum-Hansen H, Stenager E, Koch-Henriksen N. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004; 127(4):844-850.
26. WallinMT, PageWF, Kurtzke JF. Epidemiology ofmultiple sclerosis inUS veterans. VIII. Long-term survival after onset of multiple sclerosis. Brain 2000; 123(Pt 8):1677-1687.
27. Tassinari T, Parodi S, Badino R, Vercelli M. Mortality trend for multiple sclerosis in Italy (1974-1993). Eur J Epidemiol 2001; 17(2):105-110.
28. Ajdacic-Gross V, Schmid M, Tschopp A, et al. Recording of multiple sclerosis in Swiss cause of death statistics. A 10-year mortality follow-up of the Bern prevalence study. Soz Praventivmed 1999; 44(1):30-35.
29. Ragonese P, Salemi G, Aridon P, et al. Accuracy of death certificates for motor neuron disease and multiple sclerosis in the province of Palermo in southern Italy. Neuroepidemiology 2002; 21(3):148-152.
30. Gronlie SA, Myrvoll E, Hansen G, Gronning M, Mellgren SI. Multiple sclerosis in north Norway, and first appearance in an indigenous population. J Neurol 2000; 247(2):129-133.
31. Milanov I, Topalov N, Kmetski T. Prevalence of multiple sclerosis in Gypsies and Bulgarians. Neuroepidemiology 1999; 18(4):218-222.
32. Tola MA, Yugueros Ml, Fernandez-Buey N, Fernandez-Herranz R. Prevalence of multiple sclerosis in Valladolid, northern Spain. J Neurol 1999; 246(3):170-174.
33. Sundstrom P, Nystrom L, Forsgren L. Prevalence of multiple sclerosis in Vasterbotten county in northern Sweden. Acta Neurol Scand 2001; 103(4):214-218.
34. Baumhackl U, Eibl G, Ganzinger U, et al. Prevalence of multiple sclerosis in Austria. Results of a nationwide survey. Neuroepidemiology 2002; 21(5):226-234.
35. Bencsik K, Rajda C, Fuvesi J, et al. The prevalence of multiple sclerosis, distribution of clinical forms of the disease and functional status of patients in Csongrad county, Hungary. Eur Neurol 2001; 46(4):206-209.
36. Merle H, Cabre P, Poman G, Gerard M, Smadja D. Optical involvement in multiple sclerosis. Results of a cross-sectional study with 57 patients from Martinique. J Fr Opthalmol 2001; 24(8):829-835.
37. Callegaro D, Goldbaum M, Morais L, et al. The prevalence of multiple sclerosis in the city of Sao Paulo, Brazil, 1997. Acta Neurol Scand 2001; 104(4):208-213.
38. Casquero P, Villosiada P, Montalban X, Torrent M. Frequency of multiple sclerosis in Menorca, Balearic islands, Spain. Neuroepidemiology 2001; 20(2):129-133.
39. Celius EG, Vandvik B. Multiple sclerosis in Osio, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur J Neurol 2001; 8(5):463-469.
40. Chancellor AM, Addidle M, Dawson K. Multiple sclerosis is more prevalent in northern New Zealand than previously reported. Intern Med J 2003; 33(3):79-83.
41. Dean G, Elian M, de Bono AG, et al. Multiple sclerosis in Malta in 1999: an update. J Neurol Neurosurg Psychiatry 2002; 73(3):256-260.
42. Forbes RB, Wilson SV, Swingler RJ. The prevalence of multiple sclerosis in Tayside, Scotland: do latitudinal gradients really exist? J Neurol 1999; 246(11):1033-1040.
43. Forbes RB, Swingler RJ. Estimating the prevalence of multiple sclerosis in the United Kingdom by using capture-recapture methodology. Am J Epidemiol 1999; 149(11):1016-1024.
44. Ford HL, Gerry E, Johnson M, Williams R. A prospective study of the incidence, prevalence and mortality of multiple sclerosis in Leeds. J Neurol 2002; 249(3):260-265.
45. Garcia-Gallego A, Morera-Guitart J. Prevalence and characteristics of multiple sclerosis in the health district of the Marina Alta. Rev Neurol 2002; 34(8):732-737.
46. Gusev El, Zavalishin IA, Boiko AN, Khoroshilova NL, Lakovlev AP. Epidemiological characteristics of multiple sclerosis in Russia. Zh Nevrol Psikhiatr Im S S Korsakova 2002; Suppl:3-6.
47. Hein T, Hopfenmuller W. Projection of the number of multiple sclerosis patients in Germany. Nervenarzt 2000; 71(4):288-294.
48. Hernandez MA. Epidemiology of multiple sclerosis in the Canary Islands (Spain):a study on the island of La Palma. J Neurol 2002; 249(10):1378-1381.
49. Houzen H, Niino M, Kikuchi S, et al. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003; 211(1-2):49-53.
50. Itoh T, Aizawa H, Hashimoto K, et al. Prevalence of multiple sclerosis in Asahikawa, a city in northern Japan. J Neurol Sci 2003; 214(1-2):7-9.
51. Kurtzke JF, Heltberg A. Multiple sclerosis in the Faroe Islands: an epitome. J Clin Epidemiol 2001; 54(1):1-22.
52. Lau KK, Wong LK, Li LS, Chan YW, Li HL, Wong V. Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. Hong Kong Med J 2002; 8(2):77-80.
53. Mallada-Frechin J, Matias-Guiu GJ, Martin R, et al. The prevalence of multiple sclerosis in the Alcoi Health district. Rev Neurol 2000; 30(12):1131-1134.
54. Montomoli C, Allemani C, Solinas G, et al. An ecologic study of geographical variation in multiple sclerosis risk in central Sardinia, Italy. Neuroepidemiology 2002; 21(4):187-193.
55. Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Rosati G. Multiple sclerosis prevalence among Sardinians: further evidence against the latitude gradient theory. Neurol Sci 2001; 22(2):163-165.
56. Moreau T, Manceau E, Lucas B, Lemesle M, Urbinelli R, Giroud M. Incidence of multiple sclerosis in Dijon, France: a population-based ascertainment. Neurol Res 2000; 22(2):156-159.
57. Fox CM, Bensa S, Bray I, Zajicek JP. The epidemiology of multiple sclerosis in Devon:a comparison of the new and old classification criteria. J Neurol Neurosurg Psychiatry 2004; 75(1):56-60.
58. Potemkowski A. An epidemiologic survey of multiple sclerosis in the Szczecin province in Poland. Przegl Epidemiol 2001; 55(3):331-341.
59. Simmons RD, Hall CA, Gleeson P, Everard G, Casse RF, O’Brien ED. Prevalence survey of multiple sclerosis in the Australian capital territory. Intern Med J 2001; 31(3):161-167.
60. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted county, Minnesota, 1985-2000. Neurology 2003; 61(10):1373-1377.
61. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002; 58(1):136-138.
62. Pekmezovic T, Jarebinski M, Drulovic J, Stojsavljevic N, Levic Z. Prevalence of multiple sclerosis in Belgrade, Yugoslavia. Acta Neurol Scand 2001; 104(6):353-357.
63. Piperidou HN, Heliopoulos IN, Maltezos ES, Milonas IA. Epidemiological data of multiple sclerosis in the province of Evros, Greece. Eur Neurol 2003; 49(1):8-12.
64. Salemi G, Ragonese P, Aridon P, et al. Incidence of multiple sclerosis in Bagheria City, Sicily, Italy. Neurol Sci 2000; 21(6):361-365.
65. Savettieri G, Ragonese P, Aridon P, Salemi G. Epidemiology of multiple sclerosis in Sicily. Neurol Sci 2001; 22(2):175-177.
66. Nicoletti A, Sofia V, Biondi R, et al. Epilepsy and multiple sclerosis in Sicily: a population-based study. Epilepsia 2003; 44(11):1445-1448.
67. McGuigan C, McCarthy A, Quigley C, Bannan L, Hawkins SA, Hutchinson M. Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. J Neurol Neurosurg Psychiatry 2004; 75(4):572-576.
68. Sanchez JL, Aguirre C, rcos-Burgos OM, et al. Prevalence of multiple sclerosis in Colombia. Rev Neurol 2000; 31(12):1101-1103.
69. Totaro R, Marini C, Cialfi A, Giunta M, Carolei A. Prevalence of multiple sclerosis in the L’Aquila district, central Italy. J Neurol Neurosurg Psychiatry 2000; 68(3):349-352.
70. Velazquez-Quintana M, ias-lslas MA, Rivera-Olmos V, Lozano-Zarate J. Multiple sclerosis in Mexico: a multicentre study. Rev Neurol 2003; 36(11):1019-1022.
71. Modrego PJ, Pina MA. Trends in prevalence and incidence of multiple sclerosis in Bajo Aragon, Spain. J Neurol Sci 2003; 216(1):89-93.
72. Sumelahti ML, Tienari PJ, Wikstrom J, Palo J, Hakama M. Increasing prevalence of multiple sclerosis in Finland. Acta Neurol Scand 2001; 103(3):153-158.
73. McDonnell GV, Hawkins SA. Multiple sclerosis in northern Ireland: a historical and global perspective. Ulster Med J 2000; 69(2):97-105.
74. Hernandez MA. Epidemiology of multiple sclerosis. Controversies and realities. Rev Neurol 2000; 30(10):959-964.
75. Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000; 123(Pt 5):968-974.
76. Hernan MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999; 53(8):1711-1718.
77. Acheson ED. Epidemiology of multiple sclerosis. Br Med Bull 1977; 33(1):9-14.
78. Sumelahti ML, Tienari PJ, Wikstrom J, Palo J, Hakama M. Regional and temporal variation in the incidence of multiple sclerosis in Finland 1979-1993. Neuroepidemiology 2000; 19(2):67-75.
79. Vassallo L, Elian M, Dean G. Multiple sclerosis in southern Europe. II: Prevalence in Malta in 1978. J Epidemiol Community Health 1979; 33(2):111-113.
80. Dean G, Grimaldi G, Kelly R, et al. Multiple sclerosis in southern Europe. I: Prevalence in Sicily in 1975. J Epidemiol Community Health 1979; 33(2):107-110.
81. Karni A, Kahana E, Zilber N, Abramsky O, Alter M, Karussis D. The frequency of multiple sclerosis in Jewish and Arab populations in greater Jerusalem. Neuroepidemiology 2003; 22(1):82-86.
82. Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis. Clin Neurol Neurosurg 2001; 103(1):1-11.
83. McDonald WI, Compston DAS, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-127.
84. Barnett MH, Williams DB, Day S, Macaskill P, McLeod JG. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J Neurol Sci 2003; 213(1-2):1-6.
85. Sloka S. The epidemiology study in multiple sclerosis-relevance to natural history. McGill J Med 2004; 7:41-50.
86. Pryse-Phillips WE. The incidence and prevalence of multiple sclerosis in Newfoundland and Labrador, 1960-1984. Ann Neurol 1986; 20:323-328.
87. Sloka JS, Pryse-Phillips WE, Stefanelli M. Incidence and prevalence of multiple sclerosis in Newfoundland and Labrador. Can J Neurol Sci 2005; 32(1):37-42.
88. Modrego PJ, Pina MA, Simon A, Azuara MC. The interrelations between disability and quality of life in patients with multiple sclerosis in the area of Bajo Aragon, Spain: a geographically based survey. Neurorehabil Neurol Repair 2001; 15(1):69-73.
89. Schiffer RB, McDermott MP, Copley C. A multiple sclerosis cluster associated with a small, north-central Illinois community. Arch Environ Health 2001; 56(5):389-395.
90. Dean G, Elian M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63(5):565-568.
91. Gale CR, Martyn CN. Migrant studies inmultiple sclerosis. Prog Neurobiol 1995; 47(4-5):425-448.
92. Hammond SR, English D, de Wytt C, et al. The clinical profile of MS in Australia:a comparison between medium- and high-frequency prevalence zones. Neurology 1988; 38(6):980-986.
93. Detels R, Visscher BR, Haile RW, et al. Multiple sclerosis and age at migration. Am J Epidemiol 1978; 108(5):386-393.
94. Kurtzke JF. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis Neurol Sci 2000; 21(6):383-403.
95. Salemi G, Callari G, Mmino M, et al. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol Scand 2004; 110(1):23-26.
96. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127(6):1353-1360.
97. Zorgdrager A, De Keyser J. The premenstrual period and exacerbations in multiple sclerosis. Eur Neurol 2002; 48(4):204-206.
98. Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptives and the incidence of multiple sclerosis. Neurology 2000; 55(6):848-854.
99. Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol 1998; 105(12):1296-1299.
100. Alter M, Halpern L, Bornstein B. Multiple sclerosis in Israel. ArchNeurol 1962; 7:253-263.
101. Kurland L, Reed D. Geographic and climatic aspects of multiple sclerosis: a review of current hypotheses. Am J Public Health 1964; 54:588-597.
102. Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004; 61:1613-1615.
103. Chaudhuri A, Behan PO. Multiple sclerosis is not an autoimmune disease. Ann Neurol 2004; 61(1610):1512.
104. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today 1993; 14(9):426-430.
105. Steiner I, Nisipianu P, Wirguin I. Infection and the etiology and pathogenesis of multiple sclerosis. Curr Neurol Neurosci Rep 2001; 1(3):271-276.
106. Zhang SM, Willett WC, Hernan MA, Olek MJ, Ascherio A. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. Am J Epidemiol 2000; 152(11):1056-1064.
107. Sievers EJ, Heyneman CA. Relationship between vaccinations and multiple sclerosis. Ann Pharmacother 2002; 36(1):160-162.
108. Amaducci L, Arfaioli C, Inzitari D. Multiple sclerosis among shoe and leather workers; an epidemiological survey in Florence. Acta Neurol Scand 1982; 65:94-103.
109. Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurology 2004; 3:709-717.
110. Freedman DM, Dosemeci M, Alavanja MC. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup Environ Med 2000; 57(6):418-421.
111. van dM I, Ponsonby AL, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 2001; 20(3):168-174.
112. Staples JA, Ponsonby AL, Lim LL, McMichael AJ. Ecologic analysis of some immunerelated disorders, including type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environ Health Perspect 2003; 111(4):518-523.
113. Ponsonby AL, McMichael A, van dM I. Ultraviolet radiation and autoimmune disease:insights from epidemiological research. Toxicology 2002; 181-182:71-78.
114. McGrath J. Does ‘imprinting’ with low prenatal vitamin D contribute to the risk of various adult disorders? Med Hypotheses 2001; 56(3):367-371.
115. Munger KL, Zhang SM, O’Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62(1):60-65.
116. Niino M, Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Tashiro K. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci 2000; 177(1):65-71.
117. Mohr DC, Goodkin DE, Nelson S, Cox D, Weiner M. Moderating effects of coping on the relationship between stress and the development of new brain lesions in multiple sclerosis. Psychosom Med 2002; 64(5):803-809.
118. Ackerman KD, Stover A, Heyman R, et al. 2002 Robert Ader New Investigator award. Relationship of cardiovascular reactivity, stressful life events, and multiple sclerosis disease activity. Brain Behav Immun 2003; 17(3):141-151.
119. Martinelli V. Trauma, stress and multiple sclerosis. Neurol Sci 2000; 21(4):S849-S852.
120. Mohr DC, Goodkin D, Bacchetti P, et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 2000; 55(1):55-61.
121. Schwartz CE, Foley FW, Rao SM, et al. Stress and course of disease in multiple sclerosis. Behav Med 1999; 25(3):110-116.
122. Buljevac D, Flach HZ, Hop WC. Self-reported stressful life events and exacerbations in multiple sclerosis; a prospective study. BMJ 2003; 327(7416):646.
123. Ogawa G, Mochizuki H, Kanzaki M, Kaida K, Motoyoshi K, Kamakura K. Seasonal variation of multiple sclerosis exacerbations in Japan. Neurol Sci 2004; 24(6):417-419.
124. Oikonen M, Laaksonen M, Laippala P, et al. Ambient air quality and occurrence of multiple sclerosis relapse. Neuroepidemiology 2003; 22(1):95-99.
125. Gilden DH. Multiple sclerosis exacerbations and infection. Lancet Neurol 2002; 1:145.
126. Leibowitz U, Antonovsky A, Medalie JM, et al. Epidemiological study of multiple sclerosis in Israel; II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 1966; 29:60-68.
127. Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2004; 347(12):911-920.
128. Granieri E, Casetta I, Tola MR, Ferrante P. Multiple sclerosis: infectious hypothesis. Neurol Sci 2001; 22(2):179-185.
129. Bachmann S, Kesselring J. Multiple sclerosis and infectious childhood diseases. Neuroepidemiology 1998; 17(3):154-160.
130. Kazmierski R, Wender M, Guzik P, Zielonka D. Association of influenza incidence with multiple sclerosis onset. Folia Neuropathol 2004; 42(1):19-23.
131. Wagner HJ, Hennig H, Jabs WJ, Siekhaus A, Wessel K, Wandinger KP. Altered prevalence and reactivity of anti-Epstein-Barr virus antibodies in patients with multiple sclerosis. Viral Immunol 2000; 13(4):497-502.
132. Munger KL, Peeling RW, Hernan MA, et al. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology 2003; 14(2):141-147.
133. Munger KL, DeLorenze GN, Levin LI, et al. A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts. Neurology 2004; 62:1799-1803.
134. Krametter D, Niederwieser G, Berghold A, et al. Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker. Mult Scler 2001; 7(1):13-18.
135. Clark DA. Human herpesvirus 6. Rev Med Virol 2000; 10(3):155-173.
136. Enbom M. Human herpesvirus 6 in the pathogenesis of multiple sclerosis. APMIS 2001; 109(6):401-411.
137. Alvarez R, Cour I, Kanaan A, et al. Detection of viral genomes of the Herpesviridae family in multiple sclerosis patients by means of the polymerase chain reaction (PCR). Enferm Infec Microbiol Clin 2000; 18(5):223-228.
138. Moore FG, Wolfson C. Human herpes virus 6 and multiple sclerosis. Acta Neurol Scand 2002; 106(2):63-83.
139. Tomsone V, Logina I, Millers A, Chapenko S, Kozireva S, Murovska M. Association of human herpesvirus 6 and human herpesvirus 7 with demyelinating diseases of the nervous system. J Neurovirol 2001; 7(6):564-569.
140. Al-Shammari S, Nelson RF, Voevodin A. HHV-6 DNAaemia in patients with multiple sclerosis in Kuwait. Acta Neurol Scand 2003; 107(2):122-124.
141. Gutierrez J, Vergara MJ, Guerrero M, et al. Multiple sclerosis and human herpesvirus 6. Infection 2002; 30(3):145-149.
142. Alvarez-Lafuente R, De las Heras V, Bartolemé M, et al. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch Neurol 2004; 61:1523-1527.
143. Ferrante P, Mancuso R, Pagani E, et al. Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack. J Neurovirol 2000; 6(suppl 2):S109-S114.
144. Ross RT, Cheang M, Landry G, Klassen L, Doerksen K. Herpes zoster and multiple sclerosis. Can J Neurol Sci 1999; 26(1):29-32.
145. Marrie RA, Wolfson C. Multiple sclerosis and varicella zoster virus infection: a review. Epidemiol Infect 2001; 127(2):315-325.
146. Touze E, Fourrier A, Rue-Fenouche C, et al. Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology 2002; 21(4):180-186.
147. Sadovnick AD, Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 2000; 355(9203):549-550.
148. Monteyne P, Andre FE. Is there a causal link between hepatitis B vaccination and multiple sclerosis? Vaccine 2000; 18(19):1994-2001.
149. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. Neurology 2004; 63:838-342.
150. Naismith RT, Cross AH. Does the hepatitis B vaccine cause multiple sclerosis? Neurology 2004; 63:772-773.
151. Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002; 125(Pt 5):952-960.
152. Dolei A, Serra C, Mameli G, et al. Multiple sclerosis-associated retrovirus (MSRV) in Sardinian MS patients. Neurology 2002; 58(3):471-473.
153. Marrie RA, Wolfson C, Sturkenboom MC, et al. Multiple sclerosis and antecedent infections: a case-control study. Neurology 2000; 54(12):2307-2310.
154. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994; 36:S25-S28.
155. Kriesel JD, White A, Hayden FG, Spruance SL, Petajan J. Multiple sclerosis attacks are associated with picornavirus infections. Mult Scler 2004; 10(2):145-148.
156. Stüve O, Racke M, Hemmer B. Viral pathogens in multiple sclerosis. Arch Neurol 2004; 61:1500-1502.
157. Henderson RD, Bain CJ, Pender MP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci 2000; 7(5):434-437.
158. Sloka S. Observations on recent studies showing increased co-occurrence of autoimmune diseases. J Autoimmun 2002; 18(3):251-257.
159. Tremlett HL, Evans J, Wiles CM, Luscombe DK. Asthma and multiple sclerosis: an inverse association in a case-control general practice population. QJM 2002; 95(11):753-756.
160. Broadley SA, Deans J, Chataway SJ, Sawcer SJ, Compston DA. Multiple sclerosis and tonsillectomy: no evidence for an influence on the development of disease or clinical phenotype. Mult Scler 2000; 6(2):121-123.
161. Weatherby SJ. Organic solvents and the risk of multiple sclerosis. Epidemiology 2003; 14(4):506.
162. Falaschi P, Martocchia A, Proietti A, D’Urso R, Antonini G. High incidence of hyperandrogenism- related clinical signs in patients with multiple sclerosis. Neuroendocrinol Lett 2001; 22(4):248-250.
163. Kimura K, Hunter SF, Thollander MS, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc 2000; 75(8):802-806.
164. Marrosu MG, Cocco E, Lai M, Spinicci G, Pischedda MP, Contu P. Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet 2002; 359(9316):1461-1465.
165. Zorzon M, Zivadinov R, Nasuelli D, et al. Risk factors of multiple sclerosis: a case- control study. Neurol Sci 2003; 24(4):242-247.
166. Tosti ME, Traversa G, Bianco E, Mele A. Multiple sclerosis and vaccination against hepatitis B: analysis of risk benefit profile. Ital J Gastroenterol Hepatol 1999; 31(5):388-391.
167. Offit PA, Hackett CJ. Addressing parents’ concerns: do vaccines cause allergic or autoimmune diseases? Pediatrics 2003; 111(3):653-659.
168. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000; 123(Pt 6):1102-1111.
169. Niederwieser G, Buchinger W, Bonelli RM, et al. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J Neurol 2003; 250(6):672-675.
170. Sakuma R, Fujihara K, Sato N, Mochizuki H, Itoyama Y. Optic-spinal form of multiple sclerosis and anti-thyroid autoantibodies. J Neurol 1999; 246(6):449-453.
171. De SJ, Devos D, Castelnovo G, et al. The prevalence of Sjogren syndrome in patients with primary progressive multiple sclerosis. Neurology 2001; 57(8):1359-1363.
172. Hjalgrim H, Rasmussen S, Rostgaard K, et al. Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst 2004; 96(10):780-784.
173. Annunziata P, Morana P, Giorgio A, et al. High frequency of psoriasis in relatives is associated with early onset in an Italian multiple sclerosis cohort. Acta Neurol Scand 2003; 108(5):327-331.
174. Nielsen NM, Wohlfahrt J, Melbye M, et al. A Danish historical cohort study. Multiple sclerosis and poliomyelitis. Acta Neurol Scand 2000; 101(6):384-387.
175. Scott TF, Schramke CJ, Novero J, et al. Short-term prognosis in early relapsing- remitting multiple sclerosis. Neurology 2000; 55(5):689-693.
176. Hammond SR, McLeod JG, Macaskill P, English DR. Multiple sclerosis in Australia:prognostic factors. J Clin Neurosci 2000; 7(1):16-19.
177. Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168(2):96-106.
178. Achiron A, Barak Y. Multiple sclerosis-from probable to definite diagnosis. Arch Neurol 2000; 57:974-979.
179. Hawkins SA, McDonnell G. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. JNeurolNeurosurg Psychiatry 1999; 67:148-152.
180. Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 2001; 189(1-2):13-21.
181. McDonnell GV, Hawkins SA. An assessment of the spectrum of disability and handicap in multiple sclerosis: a population-based study. Mult Scler 2001; 7(2):111-117.
182. Ghezzi A, Pozzilli C, Liguori M, et al. Prospective study of multiple sclerosis with early onset. Mult Scler 2002; 8(2):115-118.
183. Simone IL, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002; 59(12):1922-1928.
184. Liguori M, Marrosu MG, Pugliatti M, et al. Age at onset in multiple sclerosis. Neurol Sci 2000; 21(4 suppl 2):S825-S829.
185. Moris G, Berciano J, Miro J. A clinical longitudinal study of multiple sclerosis in Cantabria, Spain. Neurologia 2003; 18(10):723-730.
186. Silva A, Sa MJ. Young-onset multiple sclerosis. Rev Neurol 1999; 28(11):1036-1040.
187. Polliack ML, Barak Y, Achiron A. Late-onset multiple sclerosis. J Am Geriatr Soc 2001; 49(2):168-171.
188. Trojano M, Liguori M, Bosco ZG, et al. Age-related disability in multiple sclerosis. Ann Neurol 2002; 51(4):475-480.
189. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004; 56(2):303-306.
190. Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis:the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol 1999; 246(9):770-775.
191. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003; 121 (7):944-949.
192. Optic Neuritis Study Group. Neurologic impairment 10 years after optic neuritis. Arch Neurol 2004; 61:1386-1389.
193. Pokroy R, Modi G, Saffer D. Optic neuritis in an urban black African community. Eye 2001; 15(Pt 4):469-473.
194. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60(5):848-853.
195. Wingerchuk DM, Weinshenker B. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60(5):848-853.
196. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46(4):907-911.
197. McDonnell GV, Hawkins SA. Primary progressive multiple sclerosis: increasing clarity but many unanswered questions. J Neurol Sci 2002; 199(1-2):1-15.
198. Bashir K, Whitaker JN. Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology 1999; 53(4):765-771.
199. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999; 122(Pt 10):1941-1950.
200. Montalban X, Rio J. Primary progressive multiple sclerosis. Neurol Sci 2001; 22(suppl 2):S41-S48.
201. Thompson AJ, Miller DH, Brochet B, et al. Primary progressive multiple sclerosis. Brain 1997; 120(6):1085-1096.
202. Prat A, Pelletier D, Duquette P, et al. Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume. Ann Neurol 2000; 47(2):234-237.
203. Weinshenker BG. Progressive forms of MS: classification streamlined or consensus overturned? Lancet 2000; 355(9199):162-163.
204. Lucchinetti C, Bruck W, Parisi J, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999; 122(Pt 12):2279-2295.
205. Lucchinetti C, Bruck W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol 2001; 14(3):259-269.
206. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002; 59(5):674-678.
207. Feinstein A, O’Connor P, Gray T, Feinstein K. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler 1999; 5(5):323-326.
208. Walsh SJ, DeChello LM. Excess autoimmune disease mortality among school teachers. J Rheumatol 2001; 28(7):1537-1545.
209. Axelson O, Landtblom AM, Flodin U. Multiple sclerosis and ionizing radiation. Neuroepidemiology 2001; 20(3):175-178.
210. Bolviken B, Celius EG, Nilsen R, Strand T. Radon: a possible risk factor in multiple sclerosis. Neuroepidemiology 2003; 22(1):87-94.
211. Ghadirian P, Dadgostar B, Azani R, Maisonneuve P. A case-control study of the association between socio-demographic, lifestyle and medical history factors and multiple sclerosis. Can J Public Health 2001; 92(4):281-285.
212. Hernan MA, Oleky MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001; 154(1):69-74.
213. Hakansson N, Gustavsson P, Johansen C, Floderus B. Neurodegenerative diseases in welders and other workers exposed to high levels of magnetic fields. Epidemiology 2003; 14(4):420-426.
214. Casetta I, Invernizzi M, Granieri E. Multiple sclerosis and dental amalgam: case- control study in Ferrara, Italy. Neuroepidemiology 2001; 20(2):134-137.
215. McGrother CW, Dugmore C, PhillipsMJ, Raymond NT, Garrick P, Baird WO. Multiple sclerosis, dental caries and fillings: a case-control study. Br Dent J 1999; 187(5):261-264.
216. Riise T, Moen BE, Kyvik KR. Organic solvents and the risk of multiple sclerosis. Epidemiology 2002; 13(6):718-720.
217. Spirin NN, Kachura DA, Kachura AN, Boiko AN. The influence of environmental factors on the incidence and prevalence of multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova 2003; Spec No 2:111-113.
218. Weinstock JV, Summers RW, Elliott DE, Qadir K, Urban JF Jr, Thompson R. The possible link between de-worming and the emergence of immunological disease. J Lab Clin Med 2002; 139(6):334-338.
219. Bager P, Nielsen NM, Bihmann K, et al. Childhood infections and risk of multiple sclerosis. Brain 2004; 127(Pt 11):2491-2497.
220. Sloka S, Pryse-Phillips WE, Stefanelli M, Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J Autoimmune Dis. 2005; 2(1):9.